MX343669B - Combinacion de inhibidores de la cinasa de control 1 inhibidores de la cinasa wee 1. - Google Patents
Combinacion de inhibidores de la cinasa de control 1 inhibidores de la cinasa wee 1.Info
- Publication number
- MX343669B MX343669B MX2013005471A MX2013005471A MX343669B MX 343669 B MX343669 B MX 343669B MX 2013005471 A MX2013005471 A MX 2013005471A MX 2013005471 A MX2013005471 A MX 2013005471A MX 343669 B MX343669 B MX 343669B
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitors
- kinase
- combination
- wee
- checkpoint
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se proporciona una combinación de un inhibidor CHK1 y un inhibidor WEE1.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41433710P | 2010-11-16 | 2010-11-16 | |
US201161454488P | 2011-03-18 | 2011-03-18 | |
PCT/US2011/060998 WO2012074754A1 (en) | 2010-11-16 | 2011-11-16 | Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013005471A MX2013005471A (es) | 2013-09-02 |
MX343669B true MX343669B (es) | 2016-11-16 |
Family
ID=45217677
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013005471A MX343669B (es) | 2010-11-16 | 2011-11-16 | Combinacion de inhibidores de la cinasa de control 1 inhibidores de la cinasa wee 1. |
Country Status (12)
Country | Link |
---|---|
US (2) | US9370567B2 (es) |
EP (1) | EP2640386B1 (es) |
JP (2) | JP6091422B2 (es) |
KR (1) | KR101884960B1 (es) |
CN (2) | CN108721284A (es) |
BR (1) | BR112013011918A2 (es) |
CA (1) | CA2817968C (es) |
ES (1) | ES2621857T3 (es) |
MX (1) | MX343669B (es) |
RU (2) | RU2017127088A (es) |
TW (1) | TW201304778A (es) |
WO (1) | WO2012074754A1 (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101959887B (zh) | 2008-01-08 | 2013-07-31 | 阵列生物制药公司 | 作为激酶抑制剂的吡咯并吡啶 |
ES2392014T3 (es) | 2008-01-09 | 2012-12-03 | Array Biopharma, Inc. | Pirazolopiridinas como inhibidores de la cinasa |
AR071717A1 (es) | 2008-05-13 | 2010-07-07 | Array Biopharma Inc | Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer. |
US8481557B2 (en) | 2009-04-11 | 2013-07-09 | Array Biopharma Inc. | Method of treatment using checkpoint kinase 1 inhibitors |
WO2012074754A1 (en) | 2010-11-16 | 2012-06-07 | Array Biopharma Inc. | Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors |
WO2013039854A1 (en) * | 2011-09-15 | 2013-03-21 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer |
WO2014062454A1 (en) * | 2012-10-15 | 2014-04-24 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer |
CA2892361A1 (en) * | 2012-11-28 | 2014-06-05 | Merck Sharp & Dohme Corp. | Use of a wee1 inhibitor for treating a cancer characterized by low pkmyt1 expression levels |
DK2941432T3 (en) | 2012-12-07 | 2018-06-14 | Vertex Pharma | 2-amino-6-fluoro-N- (5-fluoro-4- (4- (4- (oxetan-3-yl) piperazine-1-carbonyl) piperidin-1-yl) pyridine-3-yl) pyrazolo [ 1,5ALPHA] PYRIMIDIN-3-CARBOXAMIDE AS ATR-KINASE INHIBITOR |
JP2016512815A (ja) | 2013-03-15 | 2016-05-09 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Atrキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体 |
WO2014188201A2 (en) * | 2013-05-22 | 2014-11-27 | Cancer Research Technology Limited | Treatment |
US10160760B2 (en) | 2013-12-06 | 2018-12-25 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US20170095479A1 (en) * | 2014-05-29 | 2017-04-06 | Merck Sharp & Dohme Corp. | Methods for Treating Cancer with a WEE1 Inhibitor |
SG11201610197XA (en) | 2014-06-05 | 2017-01-27 | Vertex Pharma | Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof |
RS59054B1 (sr) * | 2014-06-17 | 2019-08-30 | Vertex Pharma | Postupak za lečenje raka korišćenjem kombinacije chk1 i atr inhibitora |
MA41599A (fr) * | 2015-02-26 | 2018-01-02 | Array Biopharma Inc | Formes cristallines d'un composé pyrrolopyridine |
US10449197B2 (en) * | 2015-07-01 | 2019-10-22 | Dignity Health | Systems and methods for treating cancer |
TWI725041B (zh) * | 2015-07-23 | 2021-04-21 | 美商美國禮來大藥廠 | 用於治療神經母細胞瘤及/或軟組織肉瘤之chk1/2抑制劑 |
US11464774B2 (en) | 2015-09-30 | 2022-10-11 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
TWI627168B (zh) * | 2015-12-07 | 2018-06-21 | 美國禮來大藥廠 | (s)-乳酸鹽 |
JP6359197B2 (ja) * | 2015-12-15 | 2018-07-18 | イーライ リリー アンド カンパニー | がんの組合せ療法 |
WO2017132928A1 (en) * | 2016-02-04 | 2017-08-10 | Pharmaengine, Inc. | 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (chk1) inhibitors, and their preparations and applications |
US20200108074A1 (en) * | 2017-03-31 | 2020-04-09 | Seattle Genetics, Inc. | Combinations of chk1- and wee1- inhibitors |
CA3059576A1 (en) | 2017-04-10 | 2018-10-18 | Sierra Oncology, Inc. | Chk1 (sra737)/parpi combination methods of inhibiting tumor growth |
WO2018191299A1 (en) * | 2017-04-10 | 2018-10-18 | Sierra Oncology, Inc. | Chk1(sra737)wee1 inhibitor combination methods of inhibiting tumor growth |
CN111587115A (zh) | 2018-01-12 | 2020-08-25 | 普罗林科斯有限责任公司 | 协同癌症治疗 |
WO2020246737A1 (ko) * | 2019-06-04 | 2020-12-10 | 사회복지법인 삼성생명공익재단 | 콰시노이드를 포함하는 거세 저항성 전립선암 치료용 조성물 |
CN110585435B (zh) * | 2019-09-25 | 2022-04-01 | 香港浸会大学深圳研究院 | 具有抗癌效果的组合物及其应用 |
CN118234493A (zh) * | 2021-10-28 | 2024-06-21 | 里科瑞尔姆Ip控股有限责任公司 | 包含wee1抑制剂和dna损伤反应(ddr)抑制剂的组合疗法 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003028724A1 (en) | 2001-10-04 | 2003-04-10 | Smithkline Beecham Corporation | Chk1 kinase inhibitors |
ES2282673T3 (es) | 2002-07-15 | 2007-10-16 | Janssen Pharmaceutica N.V. | Analogos 3-furanilo de toxoflavina como inhibidores de quinasas. |
US20050037476A1 (en) | 2003-05-29 | 2005-02-17 | Pfizer Inc | Modified Wee1, crystals of peptide: inhibitor complexes containing such modified Wee1, and methods of use thereof |
CA2539320A1 (en) * | 2003-09-17 | 2005-03-31 | Icos Corporation | Use of chk1 inhibitors to control cell proliferation |
EP1732920B1 (en) | 2004-01-05 | 2011-03-09 | AstraZeneca AB | Thiophene derivatives as chk 1 inhibitors |
GB0409080D0 (en) | 2004-04-23 | 2004-05-26 | Biofocus Discovery Ltd | Compounds which interact with protein kinases |
GB0501999D0 (en) | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
JP2008534664A (ja) | 2005-04-06 | 2008-08-28 | アストラゼネカ アクチボラグ | 置換複素環およびchk1、pdk1及びpak阻害剤としてのそれらの使用 |
DE102006005179A1 (de) | 2006-02-06 | 2007-08-09 | Merck Patent Gmbh | Aminoindazolderivate |
DE102006005180A1 (de) | 2006-02-06 | 2007-08-09 | Merck Patent Gmbh | Indazol-heteroaryl-derivate |
WO2007113671A1 (en) | 2006-04-04 | 2007-10-11 | Pfizer Products Inc. | Combination therapy of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4-yl)-1-oxo-2,6-dihydro-1h-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide |
AR060635A1 (es) | 2006-04-27 | 2008-07-02 | Banyu Pharma Co Ltd | Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer |
WO2008012635A2 (en) | 2006-07-26 | 2008-01-31 | Pfizer Products Inc. | Amine derivatives useful as anticancer agents |
CA2669982A1 (en) * | 2006-11-17 | 2008-05-29 | Schering Corporation | Combination therapy for proliferative disorders |
EA200901138A1 (ru) | 2007-03-20 | 2010-04-30 | Смитклайн Бичем Корпорейшн | Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение |
KR20090121399A (ko) | 2007-03-20 | 2009-11-25 | 스미스클라인 비참 코포레이션 | 화합물 |
WO2009004329A1 (en) | 2007-07-02 | 2009-01-08 | Cancer Research Technology Limited | 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h-1,3,6,9-tetraaza-fluorenes as chk1 kinase function inhibitors |
CN101959887B (zh) | 2008-01-08 | 2013-07-31 | 阵列生物制药公司 | 作为激酶抑制剂的吡咯并吡啶 |
ES2392014T3 (es) | 2008-01-09 | 2012-12-03 | Array Biopharma, Inc. | Pirazolopiridinas como inhibidores de la cinasa |
AR071717A1 (es) * | 2008-05-13 | 2010-07-07 | Array Biopharma Inc | Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer. |
CN102119163A (zh) | 2008-06-11 | 2011-07-06 | 健泰科生物技术公司 | 二氮杂咔唑和使用方法 |
BRPI0909957A2 (pt) | 2008-06-11 | 2016-04-19 | Genentech Inc | "composto, composição farmacêutica, método de inibir o crescimento anormal de células ou de tratar um distúrbio hiperproliferativo em um mamífero, método de tratamento do câncer em um mamífero" |
CA2745970A1 (en) | 2008-12-12 | 2010-06-17 | Msd K.K. | Dihydropyrimidopyrimidine derivative |
CA2750716A1 (en) | 2009-02-25 | 2010-09-02 | Msd K.K. | Pyrimidopyrimidoindazole derivative |
US8481557B2 (en) | 2009-04-11 | 2013-07-09 | Array Biopharma Inc. | Method of treatment using checkpoint kinase 1 inhibitors |
SG10201404012RA (en) | 2009-04-11 | 2014-09-26 | Array Biopharma Inc | Checkpoint kinase 1 inhibitors for potentiating dna damaging agents |
US20140221370A1 (en) | 2010-07-09 | 2014-08-07 | Array Biopharma Inc. | Pyrrolopyridines as kinase inhibitors |
WO2012074754A1 (en) | 2010-11-16 | 2012-06-07 | Array Biopharma Inc. | Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors |
-
2011
- 2011-11-16 WO PCT/US2011/060998 patent/WO2012074754A1/en active Application Filing
- 2011-11-16 RU RU2017127088A patent/RU2017127088A/ru not_active Application Discontinuation
- 2011-11-16 CA CA2817968A patent/CA2817968C/en active Active
- 2011-11-16 EP EP11793585.8A patent/EP2640386B1/en active Active
- 2011-11-16 CN CN201810397958.7A patent/CN108721284A/zh active Pending
- 2011-11-16 KR KR1020137015345A patent/KR101884960B1/ko active IP Right Grant
- 2011-11-16 JP JP2013539972A patent/JP6091422B2/ja not_active Expired - Fee Related
- 2011-11-16 CN CN201180065122.3A patent/CN103442710B/zh active Active
- 2011-11-16 MX MX2013005471A patent/MX343669B/es active IP Right Grant
- 2011-11-16 US US13/885,644 patent/US9370567B2/en not_active Expired - Fee Related
- 2011-11-16 ES ES11793585.8T patent/ES2621857T3/es active Active
- 2011-11-16 RU RU2013127323A patent/RU2627841C2/ru active
- 2011-11-16 BR BR112013011918-7A patent/BR112013011918A2/pt not_active Application Discontinuation
- 2011-11-16 TW TW100141872A patent/TW201304778A/zh unknown
-
2016
- 2016-05-31 US US15/169,149 patent/US10434094B2/en not_active Expired - Fee Related
- 2016-10-24 JP JP2016207633A patent/JP2017014291A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
TW201304778A (zh) | 2013-02-01 |
MX2013005471A (es) | 2013-09-02 |
CA2817968C (en) | 2019-03-12 |
RU2627841C2 (ru) | 2017-08-14 |
US9370567B2 (en) | 2016-06-21 |
BR112013011918A2 (pt) | 2020-08-25 |
EP2640386A1 (en) | 2013-09-25 |
RU2017127088A (ru) | 2019-02-04 |
US20160375002A1 (en) | 2016-12-29 |
ES2621857T3 (es) | 2017-07-05 |
CN103442710B (zh) | 2018-05-29 |
RU2013127323A (ru) | 2014-12-27 |
CA2817968A1 (en) | 2012-06-07 |
WO2012074754A1 (en) | 2012-06-07 |
CN108721284A (zh) | 2018-11-02 |
US10434094B2 (en) | 2019-10-08 |
KR101884960B1 (ko) | 2018-08-30 |
EP2640386B1 (en) | 2017-01-18 |
JP2013542997A (ja) | 2013-11-28 |
CN103442710A (zh) | 2013-12-11 |
JP2017014291A (ja) | 2017-01-19 |
KR20130114181A (ko) | 2013-10-16 |
US20130231301A1 (en) | 2013-09-05 |
JP6091422B2 (ja) | 2017-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX343669B (es) | Combinacion de inhibidores de la cinasa de control 1 inhibidores de la cinasa wee 1. | |
HK1257444A1 (zh) | Cdc7激酶抑制劑以及其用途 | |
MX355728B (es) | Inhibidores de cinasas. | |
AU333421S (en) | Showerhead | |
MX2019010602A (es) | Inhibidores de cdk. | |
CR20140332A (es) | Inhibidores de bromodominios | |
IN2015DN03795A (es) | ||
ECSP13012394A (es) | Nuevas formas de dosificación de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa | |
UY33930A (es) | Inhibidores novedosos de quinasas | |
UY33958A (es) | Inhibidores de la glucosilceramida sintasa | |
IL199727A0 (en) | Inhibitors of mek | |
JO3302B1 (ar) | باي بيريديل -ايثيل -بيرامدين مستبدل كمثبط جريلين o-أسيل ترانسفيريز | |
UY34666A (es) | Inhibidores de quinasa a base de ariléter | |
MX2015008813A (es) | Composiciones y metodos para contrarrestar la inhibicion del factor xa. | |
MX336025B (es) | Inhibidor de suciedad para zapato y sus métodos de fabricación. | |
UY34211A (es) | ?métodos y composiciones para producir arroz resistente a inhibidores de accasa?. | |
IN2013DN02552A (es) | ||
GB201211120D0 (en) | Antagonist to an enzyme and/or a metabolite of the kynurenine pathway | |
UY34800A (es) | Combinaciones farmacéuticas que contienen un inhibidor de 11-beta-hidroxiesteroide dehidrogenasa-1 útil en trastornos metabólicos | |
MX2014016005A (es) | Pildoras de desfluidización solubles en acido. | |
EP3443613B8 (en) | Subsea uninterruptible power supply | |
EP2716292A4 (en) | CDC42 INHIBITOR AND USES THEREOF | |
EP2604606A4 (en) | INHIBITOR OF CASEIN KINASE 1 AND CASEIN KINASE 1 | |
AU334539S (en) | Vibration-damping metal plate | |
MY189843A (en) | Anti-agglomerate hydrate inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |